LIQUID BIOPSY MARKET ANALYSIS

Liquid Biopsy Market, By Biomarker Type (CTC (Circulating Tumor Cells), ctNA (Circulating Tumor Nucliec Acids), Exosomes), By Sample Type (Blood, Urine, Others), By Disease Indication (Lung Cancer, Gastrointestinal Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Others), By End User (Hospitals, Cancer Institutes, Academic Institutes, Diagnostic Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027

Published In : Feb 2020
Code : CMI1223
Pages :180
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Liquid Biopsy MarketSize and Trends

The global liquid biopsy market is estimated to account for US$ 3,535.1 Mn in terms of value by the end of 2027.

Figure 1. Global Liquid Biopsy Market Value (US$ Mn), by Region, 2019

ctNA (Circulating Tumor Nucliec Acids) segment in the global liquid biopsy market was valued at US$ 250.0 Mn in 2019 and is expected to reach US$ 1,723.6 Mn by 2027 at a CAGR of 27.3% during the forecast period.

Market Trends/Key Takeaways

The use of breast milk in diagnosis of breast cancer is being tested. For instance, in February 2020, Dr. Katrina Mitchell, MD, a fellowship-trained breast surgeon of IBCLC, FACS, partnered with University of Massachusetts-Amherst cancer researchers to assess use of breast milk from nursing women for determining pathogenic BRCA1 or BRCA2 genetic mutation.

Players in the market are focused on partnering with various institutes for R&D in liquid biopsy. For instance, in February 2020, Foundation Medicine, Inc. and Chugai Pharmaceutical, Ltd. collaborated with National Cancer Center (NCC) for the use of FoundationOneLiquid, Foundation Medicine’s laboratory-developed liquid biopsy test, in the third stage of SCRUM-Japan, a cancer genomic screening consortium in Japan.

Liquid Biopsy Market Report Snapshots